These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 28527094)

  • 1. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
    Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
    Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.
    Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Zárate R; Lozano MD; Zubiri L; Perez-Gracia JL; Martín-Algarra S; González A
    Clin Chem; 2015 Jan; 61(1):297-304. PubMed ID: 25411185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
    Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B
    Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
    Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
    Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
    Puszkiel A; White-Koning M; Dupin N; Kramkimel N; Thomas-Schoemann A; Noé G; Chapuis N; Vidal M; Goldwasser F; Chatelut E; Blanchet B
    Pharmacol Res; 2016 Nov; 113(Pt A):709-718. PubMed ID: 27378568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
    Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
    Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
    Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
    Schreuer M; Meersseman G; Van Den Herrewegen S; Jansen Y; Chevolet I; Bott A; Wilgenhof S; Seremet T; Jacobs B; Buyl R; Maertens G; Neyns B
    J Transl Med; 2016 Apr; 14():95. PubMed ID: 27095081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
    Sosman JA; Kim KB; Schuchter L; Gonzalez R; Pavlick AC; Weber JS; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Hersey P; Kefford R; Lawrence D; Puzanov I; Lewis KD; Amaravadi RK; Chmielowski B; Lawrence HJ; Shyr Y; Ye F; Li J; Nolop KB; Lee RJ; Joe AK; Ribas A
    N Engl J Med; 2012 Feb; 366(8):707-14. PubMed ID: 22356324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
    Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
    Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance.
    Funck-Brentano E; Alvarez JC; Longvert C; Abe E; Beauchet A; Funck-Brentano C; Saiag P
    Ann Oncol; 2015 Jul; 26(7):1470-5. PubMed ID: 25899783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
    Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J
    JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
    Hallmeyer S; Gonzalez R; Lawson DH; Cranmer LD; Linette GP; Puzanov I; Taback B; Cowey CL; Ribas A; Daniels GA; Moore T; Gibney GT; Tawbi H; Whitman E; Lee G; Mun Y; Liu S; Hamid O
    Melanoma Res; 2017 Dec; 27(6):585-590. PubMed ID: 29076950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
    Kopetz S; Desai J; Chan E; Hecht JR; O'Dwyer PJ; Maru D; Morris V; Janku F; Dasari A; Chung W; Issa JP; Gibbs P; James B; Powis G; Nolop KB; Bhattacharya S; Saltz L
    J Clin Oncol; 2015 Dec; 33(34):4032-8. PubMed ID: 26460303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.